Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPS COMPASS Pathways	$4.80 +7.1%	$4.01	$2.49 ▼ $8.54	$449.10M	2.25	920,182 shs	3.06 million shs
KMDA Kamada	$7.22 +1.1%	$6.73	$4.74 ▼ $9.16	$415.22M	0.94	94,289 shs	60,954 shs
OPNT Opiant Pharmaceuticals		$20.58	$7.34 ▼ $29.25	$108.83M	0.84	77,920 shs	562,700 shs
PGEN Precigen	$1.49 +4.9%	$1.43	$0.65 ▼ $2.17	$439.82M	1.84	1.36 million shs	1.52 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPS COMPASS Pathways	+7.14%	+4.58%	+10.34%	+62.16%	-25.35%
KMDA Kamada	+1.12%	+3.88%	+5.87%	+8.57%	+42.69%
OPNT Opiant Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
PGEN Precigen	+4.93%	-0.67%	+9.56%	-17.22%	-5.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMPS COMPASS Pathways	2.101 of 5 stars	3.5	3.0	0.0	0.0	1.3	0.8	0.6
KMDA Kamada	4.1664 of 5 stars	3.4	3.0	0.0	0.0	3.1	1.7	3.8
OPNT Opiant Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	4.1745 of 5 stars	3.5	1.0	0.0	4.7	3.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPS COMPASS Pathways	3.00	Buy	$18.83	292.36% Upside
KMDA Kamada	2.75	Moderate Buy	$14.67	103.14% Upside
OPNT Opiant Pharmaceuticals	0.00	N/A	N/A	N/A
PGEN Precigen	3.00	Buy	$6.00	302.68% Upside

Current Analyst Ratings Breakdown

Latest OPNT, CMPS, PGEN, and KMDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	PGEN Precigen	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
5/27/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$12.00
5/15/2025	KMDA Kamada	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
5/15/2025	PGEN Precigen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/13/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $45.00
5/8/2025	KMDA Kamada	Sidoti Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
3/28/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/21/2025	KMDA Kamada	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
3/20/2025	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$2.26 per share	N/A
KMDA Kamada	$160.95M	2.58	$0.50 per share	14.52	$4.51 per share	1.60
OPNT Opiant Pharmaceuticals	$47.78M	0.00	N/A	24.75	$9.92 per share	0.00
PGEN Precigen	$3.92M	112.20	N/A	N/A	$0.13 per share	11.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPS COMPASS Pathways	-$155.12M	-$1.99	N/A	N/A	N/A	N/A	-81.75%	-59.42%	7/30/2025 (Estimated)
KMDA Kamada	$14.46M	$0.29	24.90	22.56	0.87	9.60%	6.31%	4.43%	8/13/2025 (Estimated)
OPNT Opiant Pharmaceuticals	$3.01M	-$6.56	N/A	N/A	N/A	-147.90%	-97.03%	-59.66%	N/A
PGEN Precigen	-$126.24M	-$0.56	N/A	N/A	N/A	-3,728.87%	-279.20%	-79.74%	8/13/2025 (Estimated)

Latest OPNT, CMPS, PGEN, and KMDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	KMDA Kamada	$0.07	$0.07	N/A	$0.07	$154.06 million	$44.02 million
5/14/2025	Q1 2025	PGEN Precigen	-$0.08	-$0.07	+$0.01	-$0.18	$0.50 million	$1.34 million
5/8/2025	Q1 2025	CMPS COMPASS Pathways	-$0.47	-$0.44	+$0.03	-$0.24	N/A	N/A
3/19/2025	Q4 2024	PGEN Precigen	-$0.06	-$0.04	+$0.02	-$0.06	$1.30 million	$1.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	N/A	N/A	N/A	N/A	N/A
OPNT Opiant Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPS COMPASS Pathways	0.11	10.18	10.18
KMDA Kamada	N/A	3.30	1.93
OPNT Opiant Pharmaceuticals	0.60	5.48	5.48
PGEN Precigen	N/A	3.53	3.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPS COMPASS Pathways	46.19%
KMDA Kamada	20.38%
OPNT Opiant Pharmaceuticals	42.39%
PGEN Precigen	33.51%

Insider Ownership

Company	Insider Ownership
CMPS COMPASS Pathways	3.93%
KMDA Kamada	36.10%
OPNT Opiant Pharmaceuticals	25.15%
PGEN Precigen	47.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPS COMPASS Pathways	120	93.56 million	89.89 million	Optionable
KMDA Kamada	360	57.51 million	36.75 million	Optionable
OPNT Opiant Pharmaceuticals	37	5.27 million	3.87 million	Not Optionable
PGEN Precigen	190	295.18 million	156.15 million	Optionable

OPNT, CMPS, PGEN, and KMDA Headlines

Recent News About These Companies

JMP Securities Reaffirms Market Outperform Rating for Precigen (NASDAQ:PGEN)

June 14, 2025 | americanbankingnews.com

Cantor Fitzgerald Weighs in on Precigen FY2026 Earnings

June 13, 2025 | americanbankingnews.com

Precigen (NASDAQ:PGEN) Earns Market Outperform Rating from JMP Securities

June 12, 2025 | marketbeat.com

Precigen, Inc.'s (NASDAQ:PGEN) market cap touched US$455m last week, benefiting both private equity firms who own 33% as well as institutions

June 12, 2025 | finance.yahoo.com

Cantor Fitzgerald Estimates Precigen FY2026 Earnings

June 11, 2025 | marketbeat.com

D. E. Shaw & Co. Inc. Sells 792,731 Shares of Precigen, Inc. (NASDAQ:PGEN)

May 27, 2025 | marketbeat.com

Precigen (NASDAQ:PGEN) Downgraded to "Sell" Rating by Wall Street Zen

May 26, 2025 | marketbeat.com

FY2025 EPS Estimates for Precigen Cut by Cantor Fitzgerald

May 21, 2025 | marketbeat.com

HC Wainwright Decreases Earnings Estimates for Precigen

May 21, 2025 | marketbeat.com

J.P. Morgan Sticks to Its Sell Rating for Precigen (PGEN)

May 20, 2025 | theglobeandmail.com

Precigen, Inc.: Precigen Reports First Quarter 2025 Financial Results and Business Updates

May 18, 2025 | finanznachrichten.de

Cantor Fitzgerald maintains Overweight on Precigen stock

May 17, 2025 | uk.investing.com

Precigen Reports First Quarter 2025 Financial Results and Business Updates

May 14, 2025 | prnewswire.com

Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

April 16, 2025 | prnewswire.com

Is Precigen (PGEN) The Hot Biotech Stock Under $5?

March 27, 2025 | msn.com

Precigen options imply 20.1% move in share price post-earnings

March 20, 2025 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Edwards Lifesciences (EW)

March 20, 2025 | markets.businessinsider.com

4PGEN : Expert Outlook: Precigen Through The Eyes Of 4 Analysts

March 20, 2025 | benzinga.com

Precigen, Inc.: Precigen Reports Full Year 2024 Financial Results and Business Updates

March 20, 2025 | finanznachrichten.de

Precigen Reports Progress and Financial Results for 2024

March 19, 2025 | tipranks.com

Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript

March 19, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPNT, CMPS, PGEN, and KMDA Company Descriptions

COMPASS Pathways NASDAQ:CMPS

$4.80 +0.32 (+7.14%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$4.96 +0.17 (+3.44%)

As of 06/18/2025 07:52 PM Eastern

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Kamada NASDAQ:KMDA

$7.22 +0.08 (+1.12%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$7.28 +0.06 (+0.76%)

As of 06/18/2025 05:11 PM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Opiant Pharmaceuticals NASDAQ:OPNT

Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.

Precigen NASDAQ:PGEN

$1.49 +0.07 (+4.93%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.48 -0.01 (-1.01%)

As of 06/18/2025 07:57 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time